tHEORetically Speaking
Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/
tHEORetically Speaking
Weekly News Roundup – FDA Shakeups, Novo Nordisk’s Strategic Reset, and Smart Data for Diabetes Innovation
•
HealthEconomics.com
•
Season 4
•
Episode 24
This week’s tHEORetically Speaking News Roundup covers the sudden resignation of the FDA’s top drug chief amid controversy, Novo Nordisk’s sweeping restructuring and strategic reset in the obesity and diabetes markets, and a groundbreaking data partnership between ŌURA and Tidepool driving innovation in diabetes research. We also explore how rising healthcare costs threaten the future of clinical trial diversity.
Tune in for this concise recap of these pivotal industry updates!